Results 281 to 290 of about 180,550 (320)
Revisorerklæringer: Revisors, hvervgivers og erklæringsmodtagers kendskab hertil [PDF]
Nielsen, Anita Bøgelund +1 more
core
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source
Targeting PI3Kδ in cancer: a setback or the end. [PDF]
Hao Z, Arnold S, Kolesar J.
europepmc +1 more source
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner +14 more
wiley +1 more source
The role of cystatin C in kidney injury in children and adolescents with type 1 diabetes mellitus: a systematic review. [PDF]
Gkiourtzis N +11 more
europepmc +1 more source
Förväntningsgapet mellan revisor och klient
Tobias Jonsson, Katarina Eklund
openalex +1 more source

